Omega-3 Fatty Acids (EPA/DHA) for Crohn's Disease
CEPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
The Bottom Line
EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
Key Study Findings
Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral
vs: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy
Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH)
Effect: None
None
Population: DNBS-induced Crohn's disease BALB/c mouse model
Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None
vs: None
Outcome: IBD microbiota modulation and immune regulation
Effect: None
None
Population: IBD patients (review of nutritional interventions)
Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None
vs: None
Outcome: Athletic performance and nutritional optimization
Effect: None
None
Population: Vegan athletes (narrative review)
Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None
vs: None
Outcome: Diet-genetics interaction in IBD
Effect: None
None
Population: IBD patients (editorial commentary)
Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None
vs: None
Outcome: Colitis severity
Effect: None
None
Population: Crohn's disease patients
Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95%
vs: None
Outcome: inflammation markers
Effect: None
None
Population: None
Key Statistics
6
Studies
800
Participants
↔
Mixed
C
Grade
Referenced Papers
Semergen
2025
4 citations
Current nutrition reports
2025
3 citations
Journal of ethnopharmacology
2025
1 citations
Autoimmunity reviews
2024
12 citations
World journal of …
2024
Metabolites
2023
13 citations
Scientific reports
2020
56 citations
Gastroenterology clinics of …
2018
67 citations
International journal of …
2017
143 citations
Medical principles and …
2017
45 citations
Ugeskrift for laeger
2017
European journal of …
2016
79 citations
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 citations
Clinics in dermatology
2016
19 citations
The Cochrane database …
2014
88 citations
Alimentary pharmacology & …
2013
128 citations
The British journal …
2012
145 citations
Dietary supplements for established atopic eczema.
Meta-Analysis
The Cochrane database …
2012
130 citations
World journal of …
2012
113 citations
Frontline gastroenterology
2012
20 citations
Pediatrics in review
2012
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.
Systematic Review
The American journal …
2011
946 citations
Inflammatory bowel diseases
2011
195 citations
Nutrition in clinical …
2011
1 citations
The Cochrane database …
2009
198 citations
Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Review
Alimentary pharmacology & …
2008
50 citations
The American journal …
2007
310 citations
Digestion
2007
15 citations
The Cochrane database …
2007
2 citations
Gastroenterology nursing : …
2006
24 citations
World journal of …
2005
80 citations
Alimentary pharmacology & …
2005
50 citations
Immunonutrition.
Review
Current opinion in …
2005
22 citations
Nutricion hospitalaria
2003
Journal of the …
2002
2016 citations
Enteral feeding.
Other
Current opinion in …
2002
1 citations
Enteral feeding.
Review
Current opinion in …
2002
Zeitschrift fur Gastroenterologie
1998
18 citations
Scandinavian journal of …
1996
195 citations
Arquivos de gastroenterologia
1996
Gut
1990
192 citations
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Commonly Used Dosages
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
Upper limit: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
Dosages Studied in Research
| Dosage | Duration | Effect | N |
|---|---|---|---|
| 50, 100, and 200 mg/kg oral | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | -- |
| None | -- | Mixed | 12194 |
| None | -- | Mixed | -- |
Best taken: With meals containing fat for better absorption
Safety & Side Effects
Reported Side Effects
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
Known Interactions
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
Tolerable upper intake: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
Based on 6 studies with 800 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.
Related Evidence
Other ingredients for Crohn's Disease
Omega-3 Fatty Acids (EPA/DHA) for other conditions
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.